Kidney Transplantation
517
36
51
315
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Published Results
83 trials with published results (16%)
Research Maturity
315 completed trials (61% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
7.7%
40 terminated out of 517 trials
88.7%
+2.1% vs benchmark
33%
169 trials in Phase 3/4
26%
83 of 315 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 315 completed trials
Clinical Trials (517)
Drone Transport of Deceased-Donor Kidney Grafts Between Two French Hospitals Before Transplantation: a Pilot Safety Study
Urine Testing to Detect Kidney Transplant Rejection
Noninvasive Methods to Monitor Graft Survival in Kidney Transplant Patients
Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival
Associating Renal Transplantation With the ITN Signature of Tolerance
Proteogenomic Biomarker Panels in a Serial Blood & Urine Monitoring Study of Kidney Transplant Recipients
Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen
Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation
Cardiac Improvement by Eplerenone Among Patients Under Cyclosporine or Tacrolimus for Kidney Transplantation.
The Impact of Intraoperative Diuretic Use on Delayed Graft Function Following Deceased Donor Renal Transplantation
Cell Therapy for Immunomodulation in Kidney Transplantation
Ex Vivo Normothermic Perfusion in Kidney Transplantation.
Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD
APOL1 Genetic Testing Program for Living Donors
Multiparametric MRI in a Prospective Cohort of Living Kidney Donors, Recipients, and Healthy Controls: Correlations With Markers of Renal Function, Fibrosis and Ageing
Intravenous Immunoglobulins for Prevention of BKV Infection in Kidney Transplant Recipients According to BKV Genotype-specific Neutralizing Antibody Titers at the Day of Transplantation.
Continuous Glucose Monitoring (CGM) After Kidney Transplantation
Early (Postoperative Day 3) Versus Standard (Postoperative Day 6) Urethral Catheter Removal After Living Donor Kidney Transplantation
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
Artificial Intelligence Model for Renal Allograft Rejection Identification, Lesion Quantification and Rejection Risk Prediction Based on Prospective Renal Transplant Pathology and Clinical Multidimensional Data